

# Roberto Riva

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/383322/publications.pdf>

Version: 2024-02-01

73  
papers

2,297  
citations

185998

28  
h-index

223531

46  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1783  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacokinetic Interactions Between Antiepileptic Drugs. <i>Clinical Pharmacokinetics</i> , 1996, 31, 470-493.	1.6	147
2	Free Fraction of Valproic Acid: In Vitro Timeâ€Dependent Increase and Correlation with Free Fatty Acid Concentration in Human Plasma and Serum. <i>Epilepsia</i> , 1983, 24, 65-73.	2.6	105
3	Diffusion-Tensor Magnetic Resonance Imaging Detects Normal-Appearing White Matter Damage Unrelated to Short-term Disease Activity in Patients at the Earliest Clinical Stage of Multiple Sclerosis. <i>Archives of Neurology</i> , 2005, 62, 803.	4.9	101
4	Oxcarbazepine: Pharmacokinetic Interactions and Their Clinical Relevance. <i>Epilepsia</i> , 1994, 35, S14-9.	2.6	93
5	Diurnal Fluctuations in Free and Total Steadyâ€State Plasma Levels of Carbamazepine and Correlation with Intermittent Side Effects. <i>Epilepsia</i> , 1984, 25, 476-481.	2.6	85
6	Variation in Lamotrigine Plasma Concentrations with Hormonal Contraceptive Monthly Cycles in Patients with Epilepsy. <i>Epilepsia</i> , 2006, 47, 1573-1575.	2.6	85
7	Influence of Meal Ingestion Time on Pharmacokinetics of Orally Administered Levodopa in Parkinsonian Patients. <i>Clinical Neuropharmacology</i> , 1987, 10, 527-537.	0.2	79
8	Pharmacokinetic Optimisation in the Treatment of Parkinson's Disease. <i>Clinical Pharmacokinetics</i> , 1996, 30, 463-481.	1.6	63
9	Clarithromycin-Carbamazepine Interaction: A Case Report. <i>Epilepsia</i> , 1993, 34, 161-162.	2.6	60
10	Genetic polymorphism of catechol-O-methyltransferase and levodopa pharmacokinetic-pharmacodynamic pattern in patients with Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 734-739.	2.2	60
11	Simultaneous HPLCâ€UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2010, 878, 461-465.	1.2	59
12	Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 828, 113-117.	1.2	58
13	Lacosamide Therapeutic Monitoring in Patients With Epilepsy. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 849-852.	1.0	58
14	Response to a Standard Oral Levodopa Test in Parkinsonian Patients with and without Motor Fluctuations. <i>Clinical Neuropharmacology</i> , 1990, 13, 19-28.	0.2	56
15	Levodopa Therapy Monitoring in Patients With Parkinson Disease: a Kineticâ€Dynamic Approach. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 621-629.	1.0	56
16	Levetiracetam Therapeutic Monitoring in Patients with Epilepsy. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 375-379.	1.0	52
17	Simple and validated HPLCâ€UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 873, 129-132.	1.2	51
18	Decreased Phenytoin Level During Antineoplastic Therapy: A Case Report. <i>Epilepsia</i> , 1983, 24, 75-78.	2.6	50

#	ARTICLE	IF	CITATIONS
19	Simple and rapid micromethod for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. <i>Biomedical Applications</i> , 1986, 375, 165-169.	1.7	50
20	Evidence of Polymorphic CYP2C19 Involvement in the Human Metabolism of N-Desmethyloclobazam. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 737-741.	1.0	49
21	Effect of Felbamate on Clobazam and Its Metabolite Kinetics in Patients With Epilepsy. <i>Therapeutic Drug Monitoring</i> , 1999, 21, 604.	1.0	47
22	Simple and rapid liquid chromatographic-turbo ion spray mass spectrometric determination of topiramate in human plasma. <i>Biomedical Applications</i> , 2001, 761, 133-137.	1.7	44
23	Hyperammonemia in asterix induced by carbamazepine: two case reports. <i>Acta Neurologica Scandinavica</i> , 1984, 69, 186-189.	1.0	40
24	Topiramate Therapeutic Monitoring in Patients With Epilepsy: Effect of Concomitant Antiepileptic Drugs. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 332-337.	1.0	40
25	Seizure Worsening Caused by Decreased Serum Valproate During Meropenem Therapy. <i>Journal of Child Neurology</i> , 2005, 20, 456-457.	0.7	39
26	Dopamine Transporter Gene Polymorphism, SPECT Imaging, and Levodopa Response in Patients with Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2004, 27, 111-115.	0.2	31
27	Free Concentration of Carbamazepine and Carbamazepine-10,11-Epoxyde in Children and Adults. <i>Clinical Pharmacokinetics</i> , 1985, 10, 524-531.	1.6	29
28	Determination of Total and Free Plasma Carbamazepine Concentrations by Enzyme Multiplied Immunoassay. <i>Therapeutic Drug Monitoring</i> , 1985, 7, 46-50.	1.0	28
29	Valproic Acid Free Fraction in Epileptic Children Under Chronic Monotherapy. <i>Therapeutic Drug Monitoring</i> , 1983, 5, 197-200.	1.0	27
30	Inpatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. <i>Epilepsy Research</i> , 2016, 122, 79-83.	0.8	27
31	Daily Variation in the Occurrence of Different Subtypes of Stroke. <i>Stroke Research and Treatment</i> , 2017, 2017, 1-12.	0.5	27
32	Carnitine Disposition Before and During Valproate Therapy in Patients with Epilepsy. <i>Epilepsia</i> , 1993, 34, 184-187.	2.6	26
33	Endozepines in recurrent stupor. <i>Sleep Medicine Reviews</i> , 2005, 9, 477-487.	3.8	26
34	Determination of Unbound Valproic Acid Concentration in Plasma by Equilibrium Dialysis and Gas-Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 1982, 4, 341-352.	1.0	25
35	Simple and rapid determination of propranolol and its active metabolite, 4-hydroxypropranolol, in human plasma by liquid chromatography with fluorescence detection. <i>Biomedical Applications</i> , 1982, 228, 362-365.	1.7	25
36	Free and Total Plasma Concentrations of Carbamazepine and Carbamazepine-10, 11-Epoxyde in Epileptic Patients. <i>Therapeutic Drug Monitoring</i> , 1984, 6, 408-413.	1.0	24

#	ARTICLE	IF	CITATIONS
37	Effect of valproic acid on perampanel pharmacokinetics in patients with epilepsy. <i>Epilepsia</i> , 2018, 59, e103-e108.	2.6	23
38	Free and Total Serum Concentrations of Carbamazepine and Carbamazepine-10, 11-epoxide in Infancy and Childhood. <i>Epilepsia</i> , 1985, 26, 320-322.	2.6	21
39	Clinical pharmacokinetics of pramipexole, ropinirole and rotigotine in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 61, 111-117.	1.1	18
40	Kinetic-dynamic relationship of oral levodopa: Possible biphasic response after sequential doses in Parkinson's disease. <i>Movement Disorders</i> , 1992, 7, 244-248.	2.2	17
41	Relationship Between Levodopa Concentration, Dyskinesias, and Motor Effect in Parkinsonian Patients. <i>Clinical Neuropharmacology</i> , 1997, 20, 409-418.	0.2	17
42	Simple and rapid validated HPLC-fluorescence determination of perampanel in the plasma of patients with epilepsy. <i>Practical Laboratory Medicine</i> , 2018, 10, 15-20.	0.6	17
43	Liquid chromatographic determination of flunarizine in human plasma. <i>Biomedical Applications</i> , 1986, 374, 196-199.	1.7	16
44	A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>Journal of Neurology</i> , 2007, 254, 78-83.	1.8	16
45	Unexpected gamma glutamyltransferase rise increase during levetiracetam monotherapy. <i>Epileptic Disorders</i> , 2010, 12, 81-82.	0.7	16
46	Quantitative determination of clobazam in the plasma of epileptic patients by gas-liquid chromatography with electron-capture detection. <i>Biomedical Applications</i> , 1981, 225, 219-224.	1.7	15
47	Simple and rapid GLC method for the determination of orphenadrine in human plasma. <i>Biomedical Chromatography</i> , 1987, 2, 193-194.	0.8	14
48	Pharmacokinetic Optimisation of Dopamine Receptor Agonist Therapy for Parkinson's Disease. <i>CNS Drugs</i> , 2000, 14, 439-455.	2.7	13
49	Rapid quantitative determination of underivatized carbamazepine, phenytoin, phenobarbital and p-hydroxyphenobarbital in biological fluids by packed column gas chromatography. <i>Biomedical Applications</i> , 1980, 221, 75-84.	1.7	11
50	Liquid chromatographic analysis of metoclopramide with fluorescence detection in cirrhotic patients. <i>Biomedical Chromatography</i> , 1987, 2, 135-136.	0.8	11
51	Combined Levodopa-Anticholinergic Therapy in the Treatment of Parkinson's Disease Effect on Levodopa Bioavailability. <i>Clinical Neuropharmacology</i> , 1991, 14, 148-155.	0.2	11
52	Quantitative determination of flufenamic acid in rat plasma and uterus by gas chromatography. <i>Journal of Chromatography A</i> , 1980, 192, 441-445.	1.8	10
53	Rapid quantitation of flurazepam and its major metabolite, N-desalkylflurazepam, in human plasma by gas-liquid chromatography with electron-capture detection. <i>Biomedical Applications</i> , 1981, 222, 491-495.	1.7	10
54	A Within-Subject Analysis of Carbamazepine Disposition Related to Development in Children with Epilepsy. <i>Therapeutic Drug Monitoring</i> , 1992, 14, 457-460.	1.0	10

#	ARTICLE	IF	CITATIONS
55	Assessing dopaminergic function in Parkinson's disease: levodopa kinetic-dynamic modeling and SPECT. <i>Journal of Neurology</i> , 2003, 250, 1475-1481.	1.8	10
56	Excessive Daytime Sleepiness and Levodopa in Parkinson's Disease: Polygraphic, Placebo-Controlled Monitoring. <i>Clinical Neuropharmacology</i> , 2003, 26, 115-118.	0.2	10
57	Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship. <i>Clinical Neuropharmacology</i> , 2018, 41, 171-176.	0.2	10
58	Effects of acute valproic acid administration on carnitine plasma concentrations in epileptic patients. <i>Epilepsy Research</i> , 1991, 8, 149-152.	0.8	9
59	Rapid and Simple GLC Determination of Valproic Acid and Ethosuximide in Plasma of Epileptic Patients. <i>Journal of Pharmaceutical Sciences</i> , 1982, 71, 110-111.	1.6	7
60	Clinical and EEG features of partial epilepsy with secondary bilateral synchrony. <i>Journal of Epilepsy</i> , 1995, 8, 210-214.	0.4	7
61	Validated UHPLC-MS/MS method for the simultaneous determination of pramipexole and ropinirole in plasma of patients with Parkinson's disease. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1017-1018, 114-119.	1.2	7
62	Cerebrospinal Fluid Concentrations of Nimodipine Correlate With Long-term Outcome in Aneurysmal Subarachnoid Hemorrhage: Pilot Study. <i>Clinical Neuropharmacology</i> , 2019, 42, 157-162.	0.2	7
63	Treatment of narcolepsy with cataplexy. <i>Lancet, The</i> , 2007, 369, 1081.	6.3	6
64	Simple and validated UHPLC-MS/MS analysis of nimodipine in plasma and cerebrospinal fluid of patients with subarachnoid haemorrhage. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2016, 1028, 94-99.	1.2	6
65	Novel UHPLC-MS/MS method for the determination of rotigotine in the plasma of patients with Parkinson's disease. <i>Biomedical Chromatography</i> , 2017, 31, e3944.	0.8	6
66	On the Interaction Between Phenytoin and Antineoplastic Agents. <i>Therapeutic Drug Monitoring</i> , 1985, 7, 123.	1.0	4
67	Flunarizine Plasma Concentrations and Side Effects in Migraine Patients. <i>Headache</i> , 1990, 30, 369-370.	1.8	4
68	The Effect of Entacapone on Levodopa Rate of Absorption and Latency to Motor Response in Patients With Parkinson Disease. <i>Clinical Neuropharmacology</i> , 2008, 31, 267-271.	0.2	4
69	Idiopathic Recurrent Stupor: Munchausen by Proxy and Medical Litigation. <i>Sleep</i> , 2014, 37, 211-211.	0.6	4
70	Pharmacodynamic modeling of oral levodopa in Parkinson's disease. <i>Annals of Neurology</i> , 2001, 50, 687-688.	2.8	3
71	Diurnal Fluctuations in Free and Total Plasma Concentrations of Carbamazepine at Steady-State and Correlation with Intermittent Side Effects in Epileptic Patients. <i>Clinical Pharmacokinetics</i> , 1984, 9, 93-94.	1.6	2
72	Increased Dosage of Carbidopa in Parkinsonian Patients on Low Carbidopa-Levodopa Regimen. <i>Clinical Neuropharmacology</i> , 1989, 12, 75-81.	0.2	2

#	ARTICLE	IF	CITATIONS
73	Quantitative determination of n-dipropylacetamide in the plasma of epileptic patients by gas-liquid chromatography with nitrogen-selective detection. Biomedical Applications, 1982, 233, 371-374.	1.7	1